Michael Moshman
Keine laufenden Positionen mehr
Profil
Michael Moshman has been Vice President-Chemistry, Manufacturing and Controls for Javelin Pharmaceuticals, Inc. since September 2005.
Previously, he had been Director of Clinical and Commercial Manufacturing for Javelin Pharmaceuticals since March 2002.
Mr. Moshman has 30 years of experience in pharmaceutical manufacturing and development.
He was Director of Pharmaceutical Development Services of Patheon, Inc. and Vice President of Operations of Novocol Pharmaceutical, Inc. Mr. Moshman was Director of Manufacturing for Survival Technology, Inc. He worked for Bristol Myers Squibb and Berlex Laboratories for 20 years.
Mr. Moshman has experience in business development, regulatory compliance, validation and engineering.
He received an MBA from Rutgers University and a BS in Chemistry from City College of New York.
Ehemalige bekannte Positionen von Michael Moshman
| Unternehmen | Position | Ende |
|---|---|---|
| Survival Technology, Inc. | Corporate Officer/Principal | - |
| PATHEON, INC. | Corporate Officer/Principal | - |
Novocol Pharmaceutical of Canada, Inc.
 Novocol Pharmaceutical of Canada, Inc. Pharmaceuticals: OtherHealth Technology Part of Septodont Ou Septodont SAS Ou Specialites Septodont, Novocol Pharmaceutical of Canada, Inc. manufactures dental anesthetics. Novocol Pharmaceutical of Canada was acquired by Deproco, Inc. from Henry Schein, Inc. on October 23, 2000. | Corporate Officer/Principal | - |
Javelin Pharmaceuticals, Inc.
 Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Ausbildung von Michael Moshman
| City University of New York | Undergraduate Degree |
| Rutgers State University of New Jersey | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Patheon, Inc.
 Patheon, Inc. Pharmaceuticals: MajorHealth Technology Patheon, Inc. provides drug development and manufacturing services to global pharmaceutical, biotechnology and specialty pharmaceutical companies. It operates through two segments: Commercial Manufacturing Outsourcing and Pharmaceutical Development Services. The Commercial Manufacturing Outsourcing segment manufactures prescription products in sterile dosage forms as well as solid and liquid conventional dosage forms. The Pharmaceutical Development Services segment provides a broad range of development services, including solid and sterile dosage forms. The company operates through four market segments: Biologics, Emerging Pharma, Generics and Large Pharma. Patheon was founded in 1974 and is headquartered in Mississauga, Canada. | Health Technology |
| Survival Technology, Inc. | Health Technology |
Novocol Pharmaceutical of Canada, Inc.
Novocol Pharmaceutical of Canada, Inc. Pharmaceuticals: OtherHealth Technology Part of Septodont Ou Septodont SAS Ou Specialites Septodont, Novocol Pharmaceutical of Canada, Inc. manufactures dental anesthetics. Novocol Pharmaceutical of Canada was acquired by Deproco, Inc. from Henry Schein, Inc. on October 23, 2000. | Health Technology |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | Health Technology |
